Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19018643 | 0.79 | GAA (0.51) | GAAGDAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL9576486 | 0.76 | SMN1; SMN2 (0.46) | GAAGDAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL3258892 | 0.74 | GDA (0.43) | GAAGDAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL1560676 | 0.74 | GDA (0.41) | GAAGDAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL71570 | 0.72 | — | — | |
| SCHEMBL8024 | 0.72 | — | — | |
| SCHEMBL3536595 | 0.71 | GAA (0.37) | GAAGDAL3MBTL1TDP1MAPT | |
| SCHEMBL9576447 | 0.71 | SMN1; SMN2 (0.45) | GAAL3MBTL1TDP1ALDH1A1MAPT | |
| SCHEMBL25275928 | 0.71 | GDA (0.50) | GAAGDAL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL13176680 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050142113-A1 | Antimicrobial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components | MCLEOD RIMA I (US) | 2005-06-30 | — | — | US | disclosed |
| US-6855867-B1 | Plant glutamine amidotransferase homologs | E.I. DU PONT DE NEMOURS AND COMPANY | 2005-02-15 | — | — | US | disclosed |
| US-6699654-B1 | USING INHIBITORS OF PLANT-LIKE METABOLIC PATHWAYS (NOT ASSOCIATED WITH ANIMALS, NOT ENCODED IN THE PLASTID GENOME, NOT INCLUDING PSBA OR PPI PHOSPHOFRUCTOKINASE) TO DEVELOP THE PARASITICIDE; GABACULINE AND SULFADIAZINE | MRJ TRUST C/O MARK E. RUST | 2004-03-02 | — | — | US | disclosed |
| US-20030167509-A1 | Comprises imidazoleglycerol-phosphate dehydratase activity; herbicides; fungicides | ALLEN STEPHEN M (US) | 2003-09-04 | — | — | US | disclosed |
| US-20030121072-A1 | Plant histidinol-phosphate aminotransferase homologs | ALLEN STEPHEN M (US) | 2003-06-26 | — | — | US | disclosed |
| US-20030082787-A1 | Plant histidine biosynthetic enzymes | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-05-01 | — | — | US | disclosed |
| US-6525244-B1 | Nucleic acid fragments encoding a histidine biosynthetic enzyme transduced into plants and seeds | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6441271-B1 | ISOLATED POLYNUCLEOTIDE | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-08-27 | — | — | US | disclosed |
| EP-1127144-A2 | PLANT GLUTAMINE AMIDOTRANSFERASE HOMOLOGS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000028053-A2 | PLANT GLUTAMINE AMIDOTRANSFERASE HOMOLOGS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050142113-A1 | Antimicrobial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components | POLRMT, PCK1, PSAT1 | GAA 1000/4885GDA 639/4885L3MBTL1 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.